Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 168-173 , November 2009

Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: A systematic review

  • Bradley R. Pieters

      Affiliations

    • Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, P.O. Box 22660, Z0-416, 1100 DD Amsterdam, The Netherlands.
    • ,
  • Djuna Z. de Back

      Affiliations

    • Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, The Netherlands
    • ,
  • Caro C.E. Koning

      Affiliations

    • Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, The Netherlands
    • ,
  • Aeilko H. Zwinderman

      Affiliations

    • Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, University of Amsterdam, The Netherlands

Received 25 May 2009 ,Revised 7 July 2009 ,Accepted 17 August 2009.

References 

  1. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol. 2006;24:1990–1996
  2. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  3. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233–1239
  4. Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy’s 10-year results. Int J Radiat Oncol Biol Phys. 2005;61:1306–1316
  5. Galalae RM, Kovacs G, Schultze J, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52:81–90
  6. Vargas CE, Martinez AA, Boike TP, et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int J Radiat Oncol Biol Phys. 2006;66:416–423
  7. Guix B, Bartrina JM, Henriquez I, et al. Dose escalation by combined treatment 3D-conformal radiotherapy plus HDR brachytherapy as treatment for intermediate- or high-risk cancer: early toxicity and biochemical outcome of a prospective randomized trial. Radiother Oncol. 2007;83:S39;[abstract 81]
  8. Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol. 2007;84:114–120
  9. American Society for Therapeutic Radiology and Oncology. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035–1041.
  10. Vicini FA, Horwitz EM, Kini VR, Stromberg JS, Martinez AA. Radiotherapy options for localized prostate cancer based upon pretreatment serum prostate-specific antigen levels and biochemical control: a comprehensive review of the literature. Int J Radiat Oncol Biol Phys. 1998;40:1101–1110
  11. Pieters BR, van de Kamer JB, van Herten YRJ, et al. Comparison of biologically equivalent dose–volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol. 2008;88:46–52
  12. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology. JAMA. 2000;283:2008–2012
  13. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003;57:929–943
  14. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995;32:3–12
  15. Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys. 2000;48:507–512
  16. Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70Gy at 2.5Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:904–912
  17. Zelefsky MJ, Marion C, Fuks Z, Leibel SA. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy. J Urol. 2003;170:1828–1832
  18. Pollack A, Hanlon AL, Horwitz EM, et al. Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol. 2004;171:1132–1136
  19. Nichol A, Chung P, Lockwood G, et al. A phase II study of localized prostate cancer treated to 75.6Gy with 3D conformal radiotherapy. Radiother Oncol. 2005;76:11–17
  20. Eade TN, Hanlon AL, Horwitz EM, et al. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys. 2007;68:682–689
  21. Iversen P, Bak M, Juul N, et al. Ultrasonically guided 125iodine seed implantation with external radiation in management of localized prostatic carcinoma. Urology. 1989;34:181–186
  22. Kaye KW, Olson DJ, Payne JT. Original articles: prostate cancer: detailed preliminary analysis of iodine-125 implantation for localized prostate cancer using percutaneous approach. J Urol. 1995;153:1020–1025
  23. Critz FA, Levinson AK, Williams WH, et al. Simultaneous radiotherapy for prostate cancer: 125I prostate implant followed by external-beam radiation. Cancer J Sci Am. 1998;4:359–363
  24. Ragde H, Elgamal AA, Snow PB, et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinoma. Cancer. 1998;83:989–1001
  25. Lederman GS, Cavanagh W, Albert PS, et al. Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys. 2001;49:1297–1303
  26. Potters L, Fearn P, Kattan M. The role of external radiotherapy in patients treated with permanent prostate brachytherapy. Prostate Cancer Prostatic Dis. 2002;5:47–53
  27. Singh AM, Gagnon G, Collins B, et al. Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis. Prostate. 2005;62:54–60
  28. Jani AB, Feinstein JM, Pasciak R, Krengel S, Weichselbaum RR. Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer. Urology. 2006;67:1007–1011
  29. Dattoli M, Wallner K, True L, Cash J, Sorace R. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension. Urology. 2007;69:334–337
  30. Ellis RJ, Zhou H, Kim EY, et al. Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. Brachytherapy. 2007;6:16–25
  31. Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free survival in clinical Stage T1–T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys. 2007;67:57–64
  32. Merrick GS, Butler WM, Wallner KE, et al. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys. 2007;68:34–40
  33. Lee WR, Bae K, Lawton C, et al. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of radiation therapy oncology group study 0019. Cancer. 2007;109:1506–1512
  34. Mate TP, Gottesman JE, Hatton J, Gribble M, Van Hollebeke L. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys. 1998;41:525–533
  35. Pellizzon AC, Nadalin W, Salvajoli JV, et al. Results of high dose rate after loading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiother Oncol. 2003;66:167–172
  36. Hiratsuka J, Jo Y, Yoshida K, et al. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:684–690
  37. Martin T, Roddiger S, Kurek R, et al. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol. 2004;71:35–41
  38. Åström L, Pedersen D, Mercke C, Holmang S, Johansson KA. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol. 2005;74:157–161
  39. Deger S, Boehmer D, Roigas J, et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol. 2005;47:441–448
  40. Hsu IC, Cabrera AR, Weinberg V, et al. Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer. Brachytherapy. 2005;4:202–206
  41. Chin YS, Bullard J, Bryant L, et al. High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer. Clin Oncol. 2006;18:474–479
  42. Izard MA, Haddad RL, Fogarty GB, et al. Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci 192Ir source, and neoadjuvant hormonal manipulation for prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:38–47
  43. Yamada Y, Bhatia S, Zaider M, et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy. 2006;5:157–164
  44. Rades D, Schwarz R, Todorovic M, et al. Experiences with a new high-dose-rate brachytherapy (HDR-BT) boost technique for T3b prostate cancer. Strahlenther Onkol. 2007;183:398–402
  45. Phan TP, Syed AMN, Puthawala A, Sharma A, Khan F. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol. 2007;177:123–127
  46. Kälkner KM, Wahlgren T, Ryberg M, et al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up. Acta Oncol. 2007;46:909–917
  47. Chen YC, Chuang CK, Hsieh ML, et al. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: an experience in Taiwan. Urology. 2007;70:101–105

PII: S0167-8140(09)00465-4

doi: 10.1016/j.radonc.2009.08.033

Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 168-173 , November 2009

Article Tools

* Image Usage & Resolution